|Bid||4.10 x 900|
|Ask||4.11 x 3200|
|Day's Range||4.0400 - 4.1700|
|52 Week Range||3.5400 - 33.6300|
|Beta (3Y Monthly)||2.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 18, 2017 - May 19, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
Moody's Investors Service ("Moody's") downgraded the ratings of Akorn, Inc. ("Akorn") including the Corporate Family Rating to Caa1 from B3, the Probability of Default Rating to Caa1-PD from B3-PD and the senior secured term loan rating to Caa1 from B3. Moody's also downgraded the Speculative Grade Liquidity Rating to SGL-3 from SGL-2.
Shareholder rights law firm Robbins Arroyo LLP reminds investors that a shareholder of Akorn, Inc. (AKRX) has filed a shareholder lawsuit against the company's officers and directors for breaches of fiduciary duty from 2014 through the present. Akorn is a specialty generic pharmaceutical company. According to the complaint, on April 24, 2017, Fresenius SE Co. KGaA ("Fresenius") agreed to acquire Akorn in a deal valued at $4.3 billion.
After losing a court case in Delaware last week, the CEO of drug company Akorn Inc. will step down. Last week the Supreme Court of the State of Delaware upheld a lower court’s decision to allow Fresenius Kabi AG to terminate its April 2017 $4.3 billion merger deal with Lake Forest, Illinois-based Akorn. After the court loss was announced, Akorn said CEO Raj Rai will retire.
Hedge funds run by legendary names like Nelson Peltz and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]
Akorn Inc said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE. The move comes after the Delaware Supreme Court on Friday upheld a decision by a lower court to allow Fresenius to walk away from its over $4 billion acquisition of Akorn that sent shares of the U.S generic drugmaker down more than 30 percent in regular trading. Akorn said that its Chief Executive Officer Raj Rai will retire but will remain in his post till a successor is named.
Officials of Akorn said on Friday that Chief Executive Raj Rai was retiring now that its dispute with the German pharma company had been ended by the appellate court’s decision. A panel of judges upheld a finding that a drop in revenue and other problems prior to the deal’s closing triggered Fresenius’s right to abandon the buyout. Shares of Akorn plunged Friday as much as 37 percent, to their lowest intraday price in more than eight years.
Akorn, Inc. (AKRX) today said it will move forward and rebuild shareholder value as an independent company following the disappointing decision from the Supreme Court of the State of Delaware upholding the lower court’s decision to allow Fresenius Kabi AG to terminate the April 2017 merger agreement. With the litigation process concluded, Akorn’s Board of Directors announced that it is engaged in a formal search for a new chief executive officer to lead the company into its next phase. Current CEO Raj Rai has decided to retire and will assist the board to ensure a smooth transition and remain in his role until the hiring date of the new chief executive.
Shares of Akorn plunged, dropping as much as 37 percent to their lowest intraday price in more than eight years. The case’s “record adequately supports the Court of Chancery’s determination that Akorn suffered a material adverse effect” that excused Fresenius from closing the deal, the state’s highest court said Friday.
Shares in US generic drugmaker Akorn dropped 21 per cent on Friday after a US court upheld its decision to allow Germany’s Fresenius to walk away from a $4.8bn takeover of the company. The ruling by the chief justice of the Delaware Supreme Court, the jurisdiction where most US corporate disputes are fought, ends an acrimonious dispute between the two companies that emerged after Fresenius agreed to pay a 40 per cent premium to acquire Illinois-based Akorn in April 2017. Before closing the deal, Akorn’s revenues fell sharply and a whistleblower contacted Fresenius about shortcoming in the target’s compliance with drug development standards.
LAKE FOREST, Ill., Nov. 26, 2018 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, announced that it received a new Abbreviated New Drug.
Let's see if Akorn, Inc. (AKRX) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Shares of Akorn (AKRX) fell over 48% last month, according to data provided by S&P Global Market Intelligence. The news wasn't that surprising: On the first day of October, a judge ruled that German healthcare giant Fresenius could walk away from its bid to acquire the smaller drug company for $4.75 billion. Further, Motley Fool reported that “.
The Lake Forest, Illinois-based company said it had a loss of 56 cents per share. Losses, adjusted for asset impairment costs and amortization costs, were 6 cents per share. The results did not meet Wall ...
LAKE FOREST, Ill., Nov. 06, 2018 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced its financial results for the third quarter.
LAKE FOREST, Ill., Oct. 29, 2018 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, announced that, on October 26, 2018, it received a new.
NEW YORK , Oct. 23, 2018 /PRNewswire/ -- Resideo Technologies Inc. (NYSE: REZI) will replace Akorn Inc. (NASD: AKRX) in the S&P MidCap 400, and Akorn will replace Big 5 Sporting Goods Corp. (NASD: BGFV) ...
NEW YORK, NY / ACCESSWIRE / October 22, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Akorn, Inc. (AKRX), a generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, branded as well as private-label over-the-counter consumer health products and animal health pharmaceuticals. Akorn is involved in a lawsuit with Fresenius SE for canceling a $4.3 billion buyout of AKRX. AKRX specializes in generic pharmaceutical products in alternative dosage forms.
LAKE FOREST, Ill., Oct. 18, 2018 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that the company filed a notice of appeal to.